Abstract
Alzheimer’s disease (AD) is strictly connected with aging and frailty. Although dementia contributes to frailty, it is not well established whether AD patients could be per se defined “frail”. At the same time, it is not known whether among AD patients, which are a heterogeneous group of patients, it is possible to identify a subgroup of frail individuals. In this work we sought indices useful to identify “the frail AD”. To do this we evaluated disease progression rate and response to pharmacological treatment (Mini Mental State Examination evaluation), cerebrospinal fluid biomarkers (amyloid-β42, total-tau and phospho-tau) levels, inflammatory indices (serum c-reactive protein, fibrinogen, D-Dimers) in a group of patients with a diagnosis of probable AD. Our results describe the clinical profile of patients which could be considered as non-responders and rapidly progressive AD. In the absence of other indices we conclude that patients with these features could well be considered “frail” among AD.
Keywords: Alzheimer’s disease, frailty, tau protein, amyloid-β42, mini mental state examination.
CNS & Neurological Disorders - Drug Targets
Title:Frailty Among Alzheimer’s Disease Patients
Volume: 12 Issue: 4
Author(s): Giacomo Koch, Lorena Belli, Temistocle Lo Giudice, Francesco Di Lorenzo, Giulia Maria Sancesario, Roberto Sorge, Sergio Bernardini and Alessandro Martorana
Affiliation:
Keywords: Alzheimer’s disease, frailty, tau protein, amyloid-β42, mini mental state examination.
Abstract: Alzheimer’s disease (AD) is strictly connected with aging and frailty. Although dementia contributes to frailty, it is not well established whether AD patients could be per se defined “frail”. At the same time, it is not known whether among AD patients, which are a heterogeneous group of patients, it is possible to identify a subgroup of frail individuals. In this work we sought indices useful to identify “the frail AD”. To do this we evaluated disease progression rate and response to pharmacological treatment (Mini Mental State Examination evaluation), cerebrospinal fluid biomarkers (amyloid-β42, total-tau and phospho-tau) levels, inflammatory indices (serum c-reactive protein, fibrinogen, D-Dimers) in a group of patients with a diagnosis of probable AD. Our results describe the clinical profile of patients which could be considered as non-responders and rapidly progressive AD. In the absence of other indices we conclude that patients with these features could well be considered “frail” among AD.
Export Options
About this article
Cite this article as:
Koch Giacomo, Belli Lorena, Giudice Lo Temistocle, Lorenzo Di Francesco, Sancesario Maria Giulia, Sorge Roberto, Bernardini Sergio and Martorana Alessandro, Frailty Among Alzheimer’s Disease Patients, CNS & Neurological Disorders - Drug Targets 2013; 12 (4) . https://dx.doi.org/10.2174/1871527311312040010
DOI https://dx.doi.org/10.2174/1871527311312040010 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Vascular microRNAs
Current Drug Targets Isolated Systolic Hypertension: Epidemiology, Pathogenesis and Treatment
Current Hypertension Reviews Immunosuppression in Sepsis
Current Pharmaceutical Design Platelet Activation by Extracellular Matrix Proteins in Haemostasis and Thrombosis
Current Pharmaceutical Design Post-stroke Depression Therapy: Where are we now?
Current Neurovascular Research Proinflammatory Cytokines and Sickness Behavior in Rheumatic Diseases
Current Pharmaceutical Design Plasma Glucose Concentrations and Cardiac Hypertrophy in Essential Hypertension
Current Hypertension Reviews Inhibition of Candida rugosa Lipase by Different Extracts of Five Algerian Plants and their Antioxidant Activities
Current Enzyme Inhibition 1, 2-Benzisoxazole: A Privileged Structure with a Potential for Polypharmacology
Current Pharmaceutical Design Molecular Mechanisms of Inflammation. Anti-Inflammatory Benefits of Virgin Olive Oil and the Phenolic Compound Oleocanthal
Current Pharmaceutical Design Anti-Inflammatory Agents in Ageing and Age-Associated Diseases
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Non Enzymatic Glycated Proteins in the Blood and Cardiovascular Disease
Current Pharmaceutical Design Fibrate-Associated Adverse Effects Beyond Muscle and Liver Toxicity
Current Pharmaceutical Design Cardiovascular disease management through restrained inflammatory responses
Current Pharmaceutical Design Studies on Growth Kinetics of Serratia marcescens VITSD2 and Optimization of Fermentation Conditions for Serratiopeptidase Production
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Adult Neurogenic and Antidepressant Effects of Adiponectin: A Potential Replacement for Exercise
CNS & Neurological Disorders - Drug Targets Preface
Micro and Nanosystems Association of flavonoid-rich foods and statins in the management of hypercholesterolemia: a dangerous or helpful combination?
Current Drug Metabolism Metabolic Syndrome During Menopause
Current Vascular Pharmacology Voltage-Gated Ion Channels, New Targets in Anti-Cancer Research
Recent Patents on Anti-Cancer Drug Discovery